top of page
  • Glenn Hearson

PONENTE study hits the mark in phase IIIb asthma trial

Updated: Feb 21, 2023

A study that NIHR Nottingham Biomedical Research Centre recruited asthma patients into, has announced positive results.

AstraZeneca has announced that high-level results from the PONENTE Phase IIIb open-label trial showed Fasenra (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad range of blood eosinophil counts.

On the first primary endpoint, 62% of patients achieved complete elimination of daily OCS use. On the second primary endpoint, 81% of patients achieved complete elimination or were able to reduce their daily OCS dose to 5mg or less when further reduction was not possible due to adrenal insufficiency. Both primary endpoints were sustained for at least four weeks while maintaining asthma control. PONENTE included nearly 600 patients in Europe, North America, South America, and Taiwan.


1 Comment

Nov 20, 2020

My battle with Emphysema started over 9 years ago which I finally got rid of with the help of organic treatment..I had the disease for over 9 + years..I'm in a good health now because Multivitamin herbal cure formula improve my condition drastically..the last time I went to the emergency PFT which is this year January I was told that my lung and breathing are working perfectly which was the help of this herbal medication..I don't have breathing problems anymore(Shortness of breath)..the Multivitamin herbal cure build up my lungs gradually after completing their prescription ,am able to cough it up no problem....I also met a lung specialist who told me that my lung is working perfectly so we don’t have…

bottom of page